AZADUAL works as a DNA methylation inhibitor, targeting abnormal haematopoietic cells and restoring normal blood cell production.
Recommended for:
Patients with all subtypes of myelodysplastic syndromes
Chronic myelomonocytic leukaemia
Elderly patients with acute myeloid leukaemia ineligible for intensive chemotherapy
Myelodysplastic syndrome
Acute myeloid leukaemia
Chronic myelomonocytic leukaemia
The drug is administered subcutaneously or intravenously by a medical professional. Treatment is given in cycles, often in a hospital setting. Dosage is based on body surface area, patient condition, and therapeutic response.
Contraindications:
Hypersensitivity to azacitidine
Severe hepatic impairment
Pregnancy and breastfeeding
Active infections
Side effects:
Myelosuppression (anaemia, thrombocytopenia, neutropenia)
Nausea, vomiting
Injection site reactions
Fever
Elevated liver enzymes